AbCellera To Release Top-Line Data From Phase 2 Trial Evaluating ABCL635 For Treatment Of Moderate-To-Severe Vasomotor Symptoms Due To Menopause On August 10
Management to host a conference call and live webcast at 4:30 a.m. PT / 7:30 a.m. ETAbCellera (NASDAQ:ABCL) will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of moderate-to-severe
AbCellera is sharing results from a medical test of a new menopause medicine on August 10. When a company releases test results, you can watch whether the medicine worked well—that tells you if the company's idea might become a real product.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.